Asia Pacific Drug Delivery Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular

Asia Pacific Drug Delivery Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End Users)

The Asia Pacific drug delivery market is expected to grow from US$ 4,42,973.70 million in 2023 to US$ 6,67,842.74 million by 2028. It is estimated to register a CAGR of 8.6% from 2023 to 2028.

Growing Demand for Noninvasive Drug Delivery Systems Fuel Asia Pacific Drug Delivery Market

Low patient compliance is a notable concern among physicians and medical device manufacturers. Hence, manufacturers are focusing on developing user-friendly and intuitive drug delivery systems that provide high patient comfort. Physicians, caregivers, and patients seek more patient-centric solutions, evaluating delivery systems and packaging options to encourage patients to take their medications as directed. Accurately measured doses and easy-to-use packaging with clear labeling are essential to meet self-sufficiency needs. The packaging must also be childproof, and it should prohibit counterfeiting.

Unit-dose packaging in innovative forms is increasingly used to improve patient compliance with prescribed drug therapy. A unit dose pack or container is filled precisely to contain medicines in quantities intended for a single dose. These features reduce medication errors because a drug's identity is quickly confirmed, and packaging ensures that patients take the correct dose of medicines. Drug manufacturers are now focusing on drug delivery systems that offer ease of use, portability, and convenience for patients taking drugs at locations other than home. Unither Pharmaceuticals—specializing in the development and contract manufacturing of sterile, single-dose pharmaceuticals—offers a range of convenient and easy-to-use dosage forms and delivery systems. Various forms include stick packs, single-dose vials with blow-fill-seal (BFS) technology, and effervescent tablets. Drug delivery systems that use BFS and stick-pack technologies help ensure accurate dosages and provide patients with a safer, portable, and more convenient way of adhering to their treatment regimen. These single-dose systems benefit manufacturers by aiding differentiation between different drug products and by extending product lifecycles.

Novo Nordisk has developed a FlexTouch insulin pen that requires less force to inject, an end-of-dose click to ensure accurate dose delivery, and a thin needle to reduce pain while injecting. Further, nasal sprays trickle down the throat, which is one of the main problems with nasal sprays; hence, OptiNose has developed an innovative inhaler that specifically delivers the medication in the nasal cavity. Companies also emphasize increasing convenience for patients by enabling them to use the same device they have become comfortable and familiar with to treat new indications. GlaxoSmithKline offers Breo Ellipta, an inhaler, for treating chronic obstructive pulmonary disease (COPD) and asthma patients, in addition to its initial indication as a once-a-day respiratory inhaler. A few companies are also developing devices that allow the transfer of more viscous drug products, larger molecules, and higher dose concentrations that are often difficult and painful to inject through manual delivery methods. Such innovative products help in improving patient compliance and reduce the chances of medication errors. Thus, the growing focus on patient compliance and satisfaction provides significant opportunities for the growth of the drug delivery systems market in Asia Pacific.

Asia Pacific Drug Delivery Market Overview

Asia Pacific is the fastest-growing market for drug delivery devices globally, with China, India, and Japan being the three major contributors. The Asia Pacific drug delivery market is driven by the increasing awareness of chronic disorders in the population and growing number of pharmaceutical and biotechnology companies focusing on their geographical expansion and other strategies in the countries in Asia Pacific. Additionally, the rise in research centers and government funding fuels the market growth. Also, increasing demand for therapeutics and growing medical tourism in Thailand, Singapore, and Malaysia are driving the market in this region.

Asia Pacific Drug Delivery Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Drug Delivery Market Segmentation

The Asia Pacific drug delivery market is segmented into route of administration, distribution channel, end user, and country.

Based on route of administration, the Asia Pacific drug delivery market is segmented into injectable drug delivery, oral drug delivery, transmucosal drug delivery, topical drug delivery, implantable drug delivery, and ocular drug delivery. The injectable drug delivery segment held a larger share of the Asia Pacific drug delivery market in 2023.

Based on distribution channel, the Asia Pacific drug delivery market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the Asia Pacific drug delivery market in 2023.

Based on end user, the Asia Pacific drug delivery market is segmented into hospitals and clinics, home care settings, and other end users. The hospitals and clinics segment held the largest share of the Asia Pacific drug delivery market in 2023.

Based on country, the Asia Pacific drug delivery market is segmented into Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. Japan dominated the share of the Asia Pacific drug delivery market in 2023.

Bausch Health Companies Inc, Baxter International Inc, Becton Dickinson and Co, Boehringer Ingelheim International GmbH, Boston Scientific Corp, Gerresheimer AG, GlaxoSmithKline Plc, Johnson & Johnson, Novartis AG, Novo Nordisk AS, and Pfizer Inc are the leading companies operating in the Asia Pacific drug delivery market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific drug delivery market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific drug delivery market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.